Nasdaq Xfor News Today

X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) had its target price lifted by equities researchers at HC Wainwright from $3.00 to $5.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 352.49% from the company’s […]

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Free Report) – Equities research analysts at Brookline Capital Management increased their FY2026 earnings estimates for X4 Pharmaceuticals in a research report issued to clients and investors on Monday, April 29th. Brookline Capital Management analyst L. Cann now expects that the company will earn $0.32 per share for the year, […]

HC Wainwright reiterated their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR – Free Report) in a research note released on Friday, Benzinga reports. The brokerage currently has a $3.00 price objective on the stock. Separately, B. Riley lowered X4 Pharmaceuticals from a buy rating to a neutral rating and lowered their target price for […]

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Free Report) CEO Paula Ragan sold 199,531 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $0.73, for a total transaction of $145,657.63. Following the completion of the transaction, the chief executive officer now owns 876,347 shares […]

BOSTON, Sept. 01, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Free Report) – Analysts at Zacks Small Cap boosted their Q3 2023 earnings per share (EPS) estimates for shares of X4 Pharmaceuticals in a research note issued to investors on Tuesday, August 15th. Zacks Small Cap analyst D. Bautz now expects that the company will post earnings per share of […]

X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) issued its earnings results on Thursday. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.16), MarketWatch Earnings reports. During the same quarter last year, the company earned ($0.60) earnings per share. X4 Pharmaceuticals Price Performance Shares of XFOR stock […]

HC Wainwright restated their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR – Free Report) in a research note issued to investors on Friday, Benzinga reports. The firm currently has a $3.00 price target on the stock. Separately, Stifel Nicolaus boosted their price objective on shares of X4 Pharmaceuticals from $4.00 to $5.00 in a […]

X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) is scheduled to be posting its 6/30/2023 quarterly earnings results before the market opens on Thursday, August 10th. Analysts expect X4 Pharmaceuticals to post earnings of ($0.17) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this […]

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) CEO Paula Ragan sold 6,724 shares of the firm’s stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $1.92, for a total transaction of $12,910.08. Following the completion of the transaction, the chief executive officer now directly owns 543,797 shares […]